62 related articles for article (PubMed ID: 25014961)
1. c-erbB-2 as a possible target for the use of magnetic nanoparticles in breast cancer cells.
Silva-Escobedo JG; Sanchez-Monroy V; Rojas-Lopez M; Lopez-Cruz J; González CA
IEEE Trans Nanobioscience; 2014 Sep; 13(3):300-7. PubMed ID: 25014961
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-erbB-2 in breast cancer cell lines as experimental receptor of magnetic nanoparticles.
Silva JG; Sánchez V; Polo SM; González CA
Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():4498-501. PubMed ID: 24110733
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Tissue Marked Selectively by Magnetic Nanoparticles in an Experimental Animal Model.
Silva JG; Lopez J; Sánchez V; Lozano LM; González CA
J Nanosci Nanotechnol; 2015 Dec; 15(12):9591-6. PubMed ID: 26682383
[TBL] [Abstract][Full Text] [Related]
4. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization and in vitro evaluation of exquisite targeting SPIONs-PEG-HER in HER2+ human breast cancer cells.
Almaki JH; Nasiri R; Idris A; Majid FA; Salouti M; Wong TS; Dabagh S; Marvibaigi M; Amini N
Nanotechnology; 2016 Mar; 27(10):105601. PubMed ID: 26861770
[TBL] [Abstract][Full Text] [Related]
6. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
8. A biosensor capable of identifying low quantities of breast cancer cells by electrical impedance spectroscopy.
Huerta-Nuñez LFE; Gutierrez-Iglesias G; Martinez-Cuazitl A; Mata-Miranda MM; Alvarez-Jiménez VD; Sánchez-Monroy V; Golberg A; González-Díaz CA
Sci Rep; 2019 Apr; 9(1):6419. PubMed ID: 31015522
[TBL] [Abstract][Full Text] [Related]
9. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
10. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
12. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.
Pawlowski V; Révillion F; Hornez L; Peyrat JP
Cancer Detect Prev; 2000; 24(3):212-23. PubMed ID: 10975282
[TBL] [Abstract][Full Text] [Related]
13. Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting.
Aydın RS
J Biomed Mater Res A; 2013 May; 101(5):1405-15. PubMed ID: 23086911
[TBL] [Abstract][Full Text] [Related]
14. Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors.
Hathaway HJ; Butler KS; Adolphi NL; Lovato DM; Belfon R; Fegan D; Monson TC; Trujillo JE; Tessier TE; Bryant HC; Huber DL; Larson RS; Flynn ER
Breast Cancer Res; 2011 Nov; 13(5):R108. PubMed ID: 22035507
[TBL] [Abstract][Full Text] [Related]
15. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
Hoang B; Ekdawi SN; Reilly RM; Allen C
Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody.
Kocbek P; Obermajer N; Cegnar M; Kos J; Kristl J
J Control Release; 2007 Jul; 120(1-2):18-26. PubMed ID: 17509712
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
18. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Tang CK; Concepcion XZ; Milan M; Gong X; Montgomery E; Lippman ME
Cancer Res; 1999 Oct; 59(20):5315-22. PubMed ID: 10537315
[TBL] [Abstract][Full Text] [Related]
19. HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.
Corsi F; Fiandra L; De Palma C; Colombo M; Mazzucchelli S; Verderio P; Allevi R; Tosoni A; Nebuloni M; Clementi E; Prosperi D
ACS Nano; 2011 Aug; 5(8):6383-93. PubMed ID: 21790185
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
